Related Experiment Video

Updated: Aug 24, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?

Constance D Rothermel1

  • 1Pfizer, New York, New York 10017, USA. constance.rothermel@pfizer.com

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|May 6, 2004
PubMed

Insights

Antimicrobial resistance in Streptococcus pneumoniae is rising, impacting respiratory infection treatment. While direct links to treatment failure are unclear, macrolide resistance poses a risk for breakthrough infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Escalating in vitro antimicrobial resistance in respiratory pathogens like Streptococcus pneumoniae is a growing concern.
  • Current treatment guidelines for respiratory tract infections are adjusting due to penicillin and macrolide resistance in S. pneumoniae.

Purpose of the Study:

  • To evaluate the clinical implications of antimicrobial resistance in S. pneumoniae, specifically focusing on community-acquired pneumonia.
  • To assess the direct link between in vitro resistance and treatment outcomes in patients with respiratory tract infections.

Main Methods:

  • Review of recent studies assessing the impact of beta-lactam and macrolide resistance on clinical outcomes.
  • Analysis of anecdotal reports of breakthrough bacteremia in patients receiving macrolide therapy for S. pneumoniae infections.

Main Results:

  • In vitro resistance does not consistently correlate with treatment failure in community-acquired pneumonia.
  • Anecdotal evidence suggests a risk of breakthrough bacteremia with macrolide-resistant S. pneumoniae during macrolide therapy.

Conclusions:

  • While direct clinical impact of in vitro resistance is debated, macrolide-resistant pneumococci may cause breakthrough infections.
  • Continued surveillance, judicious antibiotic use, and immunization are crucial for managing drug-resistant S. pneumoniae.

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...